Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

P. Stejskal, H. Goodarzi, J. Srovnal, M. Hajdúch, LJ. van 't Veer, MJM. Magbanua

. 2023 ; 22 (1) : 15. [pub] 20230121

Language English Country England, Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23004535

Grant support
R01 CA255442 NCI NIH HHS - United States
R01 CA255442 NCI NIH HHS - United States
U54 CA274502 NCI NIH HHS - United States

BACKGROUND: Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. MAIN BODY: Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility. CONCLUSIONS: A deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004535
003      
CZ-PrNML
005      
20230425171601.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-022-01710-w $2 doi
035    __
$a (PubMed)36681803
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Stejskal, Pavel $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, 779 00, Czech Republic. pavel.stejskal@upol.cz $u Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA. pavel.stejskal@upol.cz
245    10
$a Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance / $c P. Stejskal, H. Goodarzi, J. Srovnal, M. Hajdúch, LJ. van 't Veer, MJM. Magbanua
520    9_
$a BACKGROUND: Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. MAIN BODY: Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility. CONCLUSIONS: A deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.
650    _2
$a lidé $7 D006801
650    12
$a volné cirkulující nukleové kyseliny $x genetika $7 D000073888
650    _2
$a klinická relevance $7 D000092522
650    12
$a nádory $x patologie $7 D009369
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a biologie $7 D001695
650    _2
$a RNA $7 D012313
650    12
$a nádorové cirkulující buňky $7 D009360
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Goodarzi, Hani $u Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA $u Department of Urology, University of California San Francisco, San Francisco, CA, 94158, USA
700    1_
$a Srovnal, Josef $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, 779 00, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, 779 00, Czech Republic
700    1_
$a van 't Veer, Laura J $u Department of Laboratory Medicine, University of California San Francisco, 2340 Sutter Street, San Francisco, CA, USA
700    1_
$a Magbanua, Mark Jesus M $u Department of Laboratory Medicine, University of California San Francisco, 2340 Sutter Street, San Francisco, CA, USA. mark.magbanua@ucsf.edu
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 22, č. 1 (2023), s. 15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36681803 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171558 $b ABA008
999    __
$a ok $b bmc $g 1924933 $s 1190744
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 22 $c 1 $d 15 $e 20230121 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
GRA    __
$a R01 CA255442 $p NCI NIH HHS $2 United States
GRA    __
$a R01 CA255442 $p NCI NIH HHS $2 United States
GRA    __
$a U54 CA274502 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options